Please assess the completion status of the following clinical trial:

Trial Title: Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* • Symptoms of OAB for at least six months prior to randomization~  * ≥ 8 micturitions on average/24 hours~ * ≥ 1 urgency episodes on average/24 hours~ * with or without UUIE~    * Patients dissatisfied with prior oxybutynin ER or tolterodine ER treatment. Patients must have been on either treatment for at least 1 week and up to 12 months preceding this study. It is required that either oxybutynin ER or tolterodine ER was the most recent OAB medication taken.~   * Patients without prior darifenacin treatment~Exclusion Criteria:~* • A mean daily urinary volume \>3000 mL or a mean volume voided/micturition of \>300 mL as verified in the micturition diary for two consecutive days prior to Baseline~  * Males with post-void residual (PVR) urinary volume \>200 mL at Baseline~ * Clinically predominant and bothersome stress urinary incontinence, as determined by the investigator~ * Urinary retention or clinically significant bladder outlet obstruction as determined by the investigator~Other protocol-defined inclusion / exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- 1 (Type: EXPERIMENTAL): Darifenacin

Based on this trial design, predict the completion outcome and termination type (if applicable).